Image source: MannKind.
Shares of MannKind Corporation (NASDAQ: MNKD), a biotech company primarily focused on developing treatments for diabetes, soared 15% on Wednesday, shortly after announcing that the company was making progress on an alternative to Mylan‘s (NASDAQ: MYL) asthma and allergic reaction-prevention drug, EpiPen.